16 September 2026 editorial review · Item
Siplizumab (anti-CD2): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: DESIGNATE/STRIDE terminated records and posted immune/safety tables support no interpretable clinical-preservation result and significant lymphodepletion concern. No restart found.
- Registry NCT05574335: TERMINATED; updated 2026-07-28; enrollment 8 (ACTUAL); primary completion 2025-05-14 (ACTUAL); results posted.
- Registry NCT06025110: TERMINATED; updated 2025-08-14; enrollment 9 (ACTUAL); primary completion 2025-07-24 (ACTUAL); results not posted in retrieved record.